Details of the Drug

General Information of Drug (ID: DM3XYD1)

Drug Name

Tegaserod

Synonyms

Tegaserod (USAN/INN); 1-[[(Z)-(5-methoxyindol-3-ylidene)methyl]amino]-2-pentylguanidine

Indication

Disease Entry	ICD 11	Status	REF
Irritable bowel syndrome	DD91.0	Approved	[1]
Dyspepsia	MD92	Withdrawn from market	[2]
Gastro-oesophageal reflux	DA22	Withdrawn from market	[2]
------------------------------------------------------------------------------------

Affected Organisms

Humans and other mammals

ATC Code

A06AX06: Tegaserod

A06AX: Other drugs for constipation

A06A: DRUGS FOR CONSTIPATION

A06: DRUGS FOR CONSTIPATION

A: ALIMENTARY TRACT AND METABOLISM

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

301.39

Logarithm of the Partition Coefficient (xlogp)

2.6

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption Tmax: The time to maximum plasma concentration (Tmax) is 1 h []
Bioavailability: The bioavailability of drug is 10% []
Clearance: The clearance of drug is 77 +/- 15 L/h []
Half-life: The concentration or amount of drug in body reduced by one-half in 4.6 - 8.1 hours []
Metabolism: The drug is metabolized via the way of hydrolysis and direct glucuronidation [3]
Vd: The volume of distribution (Vd) of drug is 368 +/- 223 L []

Chemical Identifiers

Formula: C16H23N5O
IUPAC Name: 1-[(E)-(5-methoxy-1H-indol-3-yl)methylideneamino]-2-pentylguanidine
Canonical SMILES: CCCCCN=C(N)N/N=C/C1=CNC2=C1C=C(C=C2)OC
InChI: InChI=1S/C16H23N5O/c1-3-4-5-8-18-16(17)21-20-11-12-10-19-15-7-6-13(22-2)9-14(12)15/h6-7,9-11,19H,3-5,8H2,1-2H3,(H3,17,18,21)/b20-11+
InChIKey: IKBKZGMPCYNSLU-RGVLZGJSSA-N

Cross-matching ID

PubChem CID: 135409453
ChEBI ID: CHEBI:51043
CAS Number: 145158-71-0
UNII: 458VC51857
DrugBank ID: DB01079
TTD ID: D00XWD
VARIDT ID: DR00018
INTEDE ID: DR1541

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
5-HT 4 receptor (HTR4)	TT07C3Y	5HT4R_HUMAN	Agonist	[4]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 2D6 (CYP2D6)_{Main DME}	DECB0K3	CP2D6_HUMAN	Substrate	[5]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Cytochrome P450 1A2 (CYP1A2)	OTLLBX48	CP1A2_HUMAN	Gene/Protein Processing	[5]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Irritable bowel syndrome

ICD Disease Classification

DD91.0

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
5-HT 4 receptor (HTR4)	DTT	HTR4	6.16E-01	-0.03	-0.24
Cytochrome P450 2D6 (CYP2D6)	DME	CYP2D6	8.70E-01	2.98E-02	1.22E-01

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 226).
3	Quinones-Lombrana A, Li N, Del Solar V, Atilla-Gokcumen GE, Blanco JG: CBR1 rs9024 genotype status impacts the bioactivation of loxoprofen in human liver. Biopharm Drug Dispos. 2018 Jun;39(6):315-318. doi: 10.1002/bdd.2135.
4	Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313.
5	In vitro metabolism of tegaserod in human liver and intestine: assessment of drug interactions. Drug Metab Dispos. 2001 Oct;29(10):1269-76.